

Chief Executive 2 Franklin Street BELFAST BT2 8DQ

Tel: 028 9536 3863 Email: FOI.BSO@hscni.net

27th January 2022

BY EMAIL

Our Ref: FOI 1630

Dear ,

Your request for information was received on 4th January 2022 and was dealt with under the terms of the Freedom of Information Act 2000. Please be advised that the Business Services Organisation (BSO) has now completed its search for the information you requested with regards to Liothyronine 5mcg Capsules:

For each Pharmacy Contractor for the last 12 months, broken down monthly:

Contractor Name and Contractor Number with number of prescriptions for Liothyronine 5mcg Capsules dispensed each month.

I wish to advise you that the information you have requested is deemed exempt.

This exemption is claimed in respect of Section 43(2) of the Freedom of Information Act 2000 (Commercial Interests). Section 43 is a qualified exemption and as such a Public Interest Test is attached.

I hope that the information provided assists you. If you are dissatisfied in any way with the handling of your request, you have the right to request a review. You should do this as soon as possible or in any case within two months of the date of issue of this letter.

In the event that you require a review to be undertaken, you can do so by writing to

Information Governance Manager, 2 Franklin Street, Belfast, BT2 8DQ



If, following an internal review, carried out by an independent decision making panel, you remain dissatisfied in any way with the handling of the request, you may make a complaint under Section 50 of the Freedom of Information Act, to the Information Commissioner's Office and ask that they investigate whether the BSO has complied with the terms of the Freedom of Information Act.

You can contact Information Commissioner at:

Website: <u>www.ico.org.uk</u> **Phone:** 0303 123 1113

Email: casework@ico.org.uk

Post: Information Commissioner's Office

3rd Floor, 14 Cromac Place

Belfast BT7 2JB

In most circumstances the Information Commissioner will not investigate a complaint unless an internal review procedure has been carried out. However the Commissioner has the option to investigate the matter at his discretion.

Yours Sincerely,

Karen Bailey.

Karen Bailey

Acting Chief Executive

Public Interest Test

| Bublic Interest Test [EOI 1620 request for Pharmacoutical data] | |
|---|---|
| Public Interest Test [FOI 1630 – request for Pharmaceutical data] | |
| Exemption claimed in respect of Section 43(2) of the Freedom of Information Act 2000 | |
| (Commercial Interests) | |
| In favour of disclosure of information | In favour of not disclosing information |
| Details of public service contractor processes require openness, transparency and accountability. There may be interest in knowing commercial activities are conducted in an open and honest way. | Disclosure of the requested data would potentially enable anyone to establish how commercially active a pharmaceutical contractor is and could cause concerns around commercial sensitivity. Disclosure therefore has the potential to cause significant detriment to the working relationship the Health and |
| | Social Care Board and the HSC Business Services Organisation has with its Community Pharmacy contractors, particularly at a time when the HSC is already under severe pressure. |
| | In order for the HSCB and BSO to provide a responsive and robust Pharmaceutical Service, they must be permitted to maintain its excellent |
| | working relationship with its Primary Care |
| | Partners. It is this working relationship |
| | which to date has ensured patient |
| | care is maintained with the minimum disruption – even throughout the COVID Pandemic. |
| | To provide the information sought would be likely to prejudice the commercial interests of any other parties involved in the process (i.e. the pharmaceutical contractors) and damage good commercial relations with the other parties. |
| | The disclosure of such information could potentially expose BSO to claims of breaches of confidentiality. |
| | Due to the impact of Brexit and the NI Protocol, HSCB and BSO are in the process of developing a Drug Tariff Intelligence Unit for Northern Ireland. Disclosing this information could undermine confidence and have a detrimental impact on the establishment |

| | of this vital unit. |
|--|---------------------|